Proteonomix, Inc. (PROT) Research

Proteonomix, Inc. is a biotechnology company focused on creating therapeutics that utilize human cells and their byproducts. Its offerings include Proteoderm, a patented anti-aging skin cream that employs a unique protein matrix to minimize wrinkles. Another product, UMK-121, targets liver disease by combining two or three existing drugs to mobilize specific bone marrow stem cells. StromaCel is an intravenous stem cell treatment for cardiac patients within two weeks of a heart attack, using donor bone marrow cells to mend heart tissue. The company also markets NC-138, another proprietary protein matrix formulated to boost skin activities that reduce the appearance of wrinkles. Established in 1995, Proteonomix, Inc. is based in Hawthorne, New Jersey, and was formerly known as National Stem Cell Holding, Inc. until its rebranding in August 2008.

Market snapshot

Symbol
PROT
Price
$0.00
Day change
0.00%
Market cap
$791.0
P/E ratio
-0.00x
52-week range
0.000001-0.0001
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Adhera Therapeutics, Inc. (ATRX)
  • Bionovate Technologies Corp (BIIO)
  • Calithera Biosciences, Inc. (CALA)
  • eFFECTOR Therapeutics, Inc. (EFTR)
  • GlobeImmune, Inc. (GBIM)
  • IMV Inc. (IMVIF)
  • Omnimmune Holdings, Inc. (OMMH)
  • OncoSec Medical Incorporated (ONCSQ)

Open Proteonomix, Inc. (PROT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.